Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

What trial are you talking about? Beth Israel Deaconess Hospital covered the costs of their research on kevetrin in combination studies with Pfizer drugs in preclinicals. So did UofB in Italy. I'm unaware of Pfizer running any kevetrin preclinicals.

With all of the problems other companies encountered with p53 drugs I expect Pfizer to simply be watching at this point, unless, they had input in the design of the current kevetrin ph2a OV trial. I don't expect them to have confidence until they see more clinical data. Mouse data won't be enough for them.

P53 research has been going on for many years now with tremendous disappointment. P53 research reminds me of Alzheimer's research in a way. Lot's of time and money thrown at it over the years. Many companies will take an interest in kevetrin if it shows success in current and upcoming trials. Oncology research is slow. Thankfully, the company has other drugs further ahead now.

It will be good to see what they come up with in the current trial. In the meantime, brilacidin is the drug of most interest to me, followed by prurisol.







In Reply to 'Amatuer17'
You are right - have asked the same questions - look at cancer compounds from BLRn, AVEn - if BP is confident they just jump with combo trials.

Fact that it is 5 years since Pfizer tried K with Stuent at DF and then just ignored it tells the story.
DF and MDA moved on to next drugs or MOA tells the same story